Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

We recently published an article titled These 10 Companies Led Monday’s Downturn. In this article, we are going to take a ...

Truist lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $120 and keeps a Buy rating on the shares. The company’s Q4 ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy. VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound.

And what's attracted a lot of attention over the past year is Viking's weight-loss drug program. The company is developing VK2735 in injectable and oral formulations. The injectable is set to ...